ALXN
Alexion Pharmaceuticals Inc
Alexion Pharmaceuticals Inc historical holders
total: 4
Third Point Alexion Pharmaceuticals Inc transactions over time
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 1
- Held since:
- 2017 Q2
- Held for:
- 2 quarters
- Latest activity:
- 2017 Q4
Daniel Loeb has been an institutional investor in Alexion Pharmaceuticals Inc (ALXN) since 2017 Q2. According to 2026 Q1 report, Daniel Loeb doesn't hold any shares. The fund/company first acquired ALXN in 2017 Q2, initially purchasing about 1.25M shares. Since the initial investment, Third Point has made 2 more transactions in this position.
When did Daniel Loeb exit their ALXN position?
Daniel Loeb no longer holds Alexion Pharmaceuticals Inc (ALXN). They sold off their entire position in 2017 Q4, closing out an investment that began in 2017 Q2.
When did Daniel Loeb first invest in ALXN?
Daniel Loeb first invested in Alexion Pharmaceuticals Inc (ALXN) in 2017 Q2 at the reported quarter-end price of $121.67 per share, acquiring 1,250,000 shares in their initial purchase.
What is Daniel Loeb's average cost basis for ALXN?
Based on historical transaction data, Daniel Loeb's estimated cost basis for Alexion Pharmaceuticals Inc (ALXN) is approximately $121.67 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $121.67
- Weighted AVG sell price:
- $140.29
ALXN transactions history by Third Point
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.